Plasma levels of soluble fibrin (SF) were measured in 1184 patients with disseminated intravascular coagulation (DIC) according to Japanese Ministry of Health and Welfare (JMHW) criteria. The usefulness of SF for the diagnosis of DIC was compared with other hemostatic molecular markers. Most hemostatic markers were significantly increased in patients with DIC than in those without DIC. Plasma levels of fibrin and fibrinogen degradation products, thrombin-antihtrombin complex, plasmin-plasmin inhibitor complex, D-dimer, thrombomodulin, and SF levels were also significantly higher in those with pre-DIC than in those without DIC. In classification of overt DIC by International Society of Thrombosis and Haemostasis (ISTH) criteria, most hemostatic markers were significantly increased Because elevated levels of circulating soluble fibrin (SF) in plasma indicate that thrombin has converted fibrinogen to fibrin, increased plasma SF levels are considered that to be a molecular marker of an impending thrombotic event. Several methods of assaying SF have been in existence for many years (1-3). Previously, most of these methods are nonspecific, semiquantitative, in patients with overt DIC than in those without overt DIC. Plasma levels of SF 'in patients with DIC were significantly higher than those in patients with pre-DIC, which were significantly higher than in those without DIC. Plasma levels of SF were also significantly higher in patients with overt DIC than in those with non-overt DIC. The correlation between plasma SF levels and DIC score according to JMHW criteria or ISTH criteria was good. Receiver operating characteristic analysis shows that SF was the best marker for the diagnosis of DIC or overt DIC. These findings suggest that plasma SF might be useful marker for the diagnosis of DIC or overt DIC.
or too laborious to be used in clinical practice (4) . Recently, several enzyme-linked immunosorbent assay systems using specific monoclonal antibody for SF have been established (5) (6) (7) . Other hemostatic molecular markers, such as D-dimer (8), thrombin-antithrombin complex (TAT) (9), plasmin-plasmin inhibitor complex (PPIC) (10) , and thrombomodulin (11) , have been developed for the diagnosis of disseminated intravascular coagulation (DIC). These markers are very sensitive but not specific for the diagnosis of DIC. These markers cannot be measured in all hospitals. DIC, which is frequently associated with obstetric diseases, malignant diseases, and severe inflammation, may cause severe bleeding and organ failure (12, 13) . The international definition and diagnostic criteria of DIC was not established in United States and Europe until 2001, although Japanese Ministry of Health and Welfare (JMHW) made the diagnostic criteria for DIC in 1987 (14) . The Japanese criteria scoring system takes into account underlying disease, bleeding symptom, organ failure, and global coagulation tests (fibrinogen, fibrin degradation products [FDP] , platelet count, and prothrombin time [PT] ).
Recently, a systemic inflammatory response syndrome (SIRS) was described in intensive care units or emergency units (15, 16) . SIRS sometimes has a poor outcome and a relationship between DIC and SIRS is being investigated. A successful trial of recombinant human activated protein C (17) for severe sepsis was recently reported; these conditions might be associated with SIRS. Studies of other anticoagulants, such as anti-thrombin (18) , thrombomodulin (19) , and tissue factor pathway inhibitor (20) , are being carried out in clinical trials for sepsis or DIC. Because severe sepsis is frequently associated with DIC, we will evaluate DIC in sepsis according to international diagnostic criteria. The Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH) subcommittee on DIC proposed the new definition of DIC and diagnostic criteria for overt-DIC in the 18th Congress of ISTH, 2001 (21) . These new criteria are also part of a scoring system according to global coagulation tests such as the criteria by JMHW.
We evaluated plasma SF levels in 1184 patients suspected to have DIC according to ISTH overt-DIC criteria and JMHW DIC criteria and examined the usefulness for the diagnosis of DIC compared to other hemostatic molecular markers.
MATERIALS AND METHODS
We evaluated 584 patients with hematopoietic malignancy and 564 patients without hematopoietic malignancy who were suspected to be associated with DIC (Table 1 ). These patients were admitted in Hospitals of Mie University.
Of 564 patients without hematopoietic malignancy, 126 patients were diagnosed as having DIC, 36 with pre-DIC, and 402 with non-DIC based on modified JMHW diagnostic criteria for DIC ( Table 2 ) (14) . The patients in whom DIC did not develop were defined as non-DIC. Pre-DIC was defined as the condition existing within at least 1 week before the onset of DIC (22) . Of 584 patients with hematopoietic tumor, 120 patients were diagnosed with DIC, 76 with pre-DIC, (21) . Organ failure was considered to have occurred in the lung when the Pao2 was; 50 mmHg or less; in the kidney when the creatinine level was 3 mg/dL or more; when symptoms of shock from heart failure were present; and when the patient was in a coma or responded only to pain. Plasma level of PT was determined with the one-stage method of Quick (23) using Thromborel S (Behringwerke, Marburg, Germany). Plasma fibrinogen was measured with clotting methods using Multiblin-U (Behringwerke). FDP was measured with the latex agglutination method using Lpia FDP (Dia-latron, Tokyo, Japan). Plasma activities of protein C and antithrombin were measured using Berichrom protein C (Behringwerke), and Berichrom antithrombin (Behringwerke). Plasma levels of TAT, PPIC, D-dimer, thrombomodulin, and tissue type plasminogen activator (tPA)/plasminogen activator inhibitor-I (PAI-I) complex were measured using the TAT test (Kokusai-Shiyaku, Kobe, Japan), PIC test (Kokusai-Shiyaku), Ddimer (Kokusai-Shiyaku), TM test (Kokusai-Shiyaku), and tPAIc test (Kokusai-Shiyaku).
Plasma SF levels were measured with latex aggregation using monoclonal antibody F405, which recognizes the oc-chain N-terminal oligopeptide of fibrin (GPRVVERERHQ) (24) .
Data are shown as mean ± SD. Statistical analysis was performed by Welch's t test and Mann-Whitney U test. The sensitivity and specificity of hemostatic molecular markers were also evaluated using a receiver operating characteristic (ROC) analysis (25) .
RESULTS
In patients with and without hematopoietic tumor, the abnormality of PT (International Normalized Ratio [INR]), platelet count, fibrinogen, antithrombin, protein C, tPA-PAI-I complex, FDP, TAT, PPIC, D-dimer, TM, and SF were more significant in patients with DIC than in those with non-DIC (p<0.01) ( Tables 3, 4 ). In those with hematopoietic tumor, FDP, TAT, PPIC, Ddimer, TM, and SF levels were also significantly higher in those with pre-DIC than in those with non-DIC. In those without hematopoietic tumor, FDP, TAT, PPIC, D-dimer, t-PA-PAI-I complex, TM, and SF levels were also significantly higher in those with pre-DIC than in those with non-DIC. In classification of overt DIC criteria, the abnormality of PT, INR, platelet count, fibrinogen, antithrombin, protein C, tPA-PAI-I complex, FDP, TAT, PPIC, D-dimer, TM, and SF were more significant in patients with overt DIC than in those without overt DIC (p<0.01) ( Table 5 ).
In both groups with and without hematopoietic tumor, plasma levels of SF were significantly higher in patients with DIC than in pre-DIC and significantly higher in patients with pre-DIC than in those with non-DIC ( Fig. 1) . Plasma levels of SF were also significantly higher in patients with overt DIC than in those with non-overt DIC. The correlation (r) between plasma SF levels and DIC score of JMHW criteria was 0.642 in patients without hematopoietic tumor and 0.614 in pa-tients with hematopoietic tumor (Fig. 2) .
Although the peak of plasma SF levels was 8 points in patients with hematopoietic tumor and 5 points in patients with hematopoietic tumor, many patients without DIC or overt DIC had high plasma SF levels. The correlation (r) between plasma SF levels and DIC score of ISTH criteria was 0.572, and the peak of plasma SF levels was 5 points. ROC analysis shows that SF was the most excellent marker for diagnosis of DIC or overt DIC (Fig. 3) . 
DISCUSSION
The Japanese diagnostic criteria for DIC (5) were established by JMHW in 1987 and in 2001 ISTH/SSC meeting proposed an international diagnostic criteria for overt DIC (18) by modification of JMHW diagnostic criteria; ISTH diagnostic criteria for overt DIC can help diagnose typical DIC. In classification of these criteria for DIC and overt DIC, abnormalities of PT, INR, platelet count, fibrinogen, antithrombin, protein C, tPA-PAI-I complex, FDP, TAT, PPIC, D-dimer, TM, and SF were significant in patients with DIC and overt DIC. FDP, TAT, PPIG, D-dimer, TM, and SF levels were also significantly high in those with pre-DIC. Prolongation of PT was important for the diagnosis of DIC (21); however, PT-INR should be used for standardization of PT value. PT-INR has already been used for monitoring of anticoagulant therapy (26) . Plasma fibrinogen levels are not sensitive, but are specific markers for the diagnosis of DIC. Indeed, plasma fibrinogen level has only 1 point in ISTH overt DIC diagnostic criteria, although it has 2 points in JMHW DIC diagnostic criteria. FDP and platelet counts are sensitive markers but not specific markers for the diagnosis of DIC. Global coagulation tests such as PT, fibrinogen, FDP, and platelet count are not adequate for the diagnosis of DIC in the early stage (27) . Plasma levels of TAT, PPIC, and D-dimer are considered to be useful markers for early stage DIC (22) . ROC analysis shows that SF was the most excellent marker for diagnosis of DIC or overt DIC. Previous ROC analysis also reported that plasma levels of SF monomer were most useful for the diagnosis of DIC (7) . In the cutoff value of SF for the diagnosis of DIC, our findings indicate that 18,ug/mL is adequate.
Recently a novel monoclonal antibody (F 405) to fibrin monomer and SF was prepared and characterized (24) . A latex-aggregation test for SF using this monoclonal antibody has been developed; this assay system is very rapid and convenient in clinical use because pre-treatment of plasma does not require as previous FM assay (7) . The correlation between plasma SF levels and DIC score of JMHW criteria or DIC score of ISTH criteria was very good and the peak of plasma SF levels was 8 points in patients without hematopoietic tumor and 5 points in patients with hematopoietic tumor. These findings indicate that plasma levels of SF are useful for the diagnosis of DIC. But, many patients without DIC had high plasma SF levels. These patients might be associated with DIC; however, these patients could not be diagnosed by JMHW or ISTH criteria. In a previous report (27) , early treatment in the pre-DIC state had a good outcome, but treatment in the overt DIC state had a poor outcome. Increased plasma SF levels in patients without DIC may suggest the pre-DIC state. Plasma levels of SF might be useful for the diagnosis of not only DIC but also pre-DIC.
